1-ethyl-2,6-dimethyl-piperidine | 38596-99-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-ethyl-2,6-dimethyl-piperidine
• 英文别名: Piperidine, 1-ethyl-2,6-dimethyl；1-ethyl-2,6-dimethylpiperidine
• CAS: 38596-99-5
• 化学式: C₉H₁₉N
• 分子量: 141.257
• InChiKey: HMVDCTBEKMKBIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• METHOD FOR PREPARING STRUCTURED DIRECTING AGENT
  申请人：Johnson Matthey Public Limited Company

  公开号：US20160304457A1

  公开（公告）日：2016-10-20

  Provided is a method for preparing a structure directing agent (SDA) for crystalline molecular sieve synthesis comprising the steps of (a) hydrolyzing analkyl sulfate counterion of a quaternary ammonium salt to produce an organic ammonium salt having a hydrogen sulfate counterion; and (b) contacting the organic ammonium salt having the hydrogen sulfate counterion with a source of hydroxide in solution to form an organic ammonium salt having a hydroxide counterion; wherein the organic ammonium salt is a structure directing agent (SDA) for crystalline molecular sieve synthesis.

  提供了一种制备用于晶体分子筛合成的结构定向剂（SDA）的方法，包括以下步骤：（a）水解季铵盐的烷基硫酸盐反离子，以产生具有氢硫酸盐反离子的有机铵盐；和（b）将具有氢硫酸盐反离子的有机铵盐与溶液中的氢氧化物源接触，形成具有氢氧化物反离子的有机铵盐；其中有机铵盐是用于晶体分子筛合成的结构定向剂（SDA）。
• [EN] AMINOTHIAZOLE DERIVATIVES USEFUL AS KLK1 INHIBITORS<br/>[FR] DÉRIVÉS AMINOTHIAZOLE UTILES COMME INHIBITEURS DE LA KLK1
  申请人：VANTIA LTD

  公开号：WO2011051673A1

  公开（公告）日：2011-05-05

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (such as asthma or COPD); and methods of treating patients which such compounds; wherein R1 to R17 and A1 are as defined herein.

  本发明提供了公式(I)的化合物：包含此类化合物的组合物；此类化合物在治疗（如哮喘或慢性阻塞性肺病（COPD））中的应用；以及使用此类化合物治疗患者的方法；其中R1至R17和A1如本文所述定义。
• CCR2 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Basak Arindrajit

  公开号：US20100234364A1

  公开（公告）日：2010-09-16

  Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists, and as controls in assays for the identification of CCR9 antagonists.

  提供了作为CCR2或CCR9受体强效拮抗剂的化合物。动物实验表明，这些化合物对于治疗炎症非常有效，而炎症是CCR2和CCR9的典型疾病。这些化合物通常是芳基磺酰胺衍生物，在制药组合物、治疗CCR2介导疾病的方法、治疗CCR9介导疾病的方法、作为CCR2拮抗剂鉴定的检测中的对照物，以及作为CCR9拮抗剂鉴定的检测中的对照物中非常有用。
• [EN] AMINOPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINOPYRIDINE
  申请人：VANTIA LTD

  公开号：WO2009133348A1

  公开（公告）日：2009-11-05

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (such as asthma or COPD); and methods of treating patients with such compounds; wherein R1 - R11 are as defined herein.

  本发明提供了式（I）的化合物：包含这些化合物的组合物；在治疗中使用这些化合物（例如哮喘或COPD）；以及使用这些化合物治疗患者的方法；其中R1 - R11如本文所定义。
• METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
  申请人：Barbay J. Kent

  公开号：US20100093702A1

  公开（公告）日：2010-04-15

  This invention relates to a novel thieno[2,3-d]pyrimidine, A, and its therapeutic and prophylactic uses, wherein R 1 and R 2 are defined in the specification. Disorders treated and/or prevented include Parkinson's Disease.

  本发明涉及一种新型噻吩[2,3-d]嘧啶A及其治疗和预防用途，其中R1和R2在说明书中有定义。治疗和/或预防的疾病包括帕金森病。